Prognostic Value of Pretreatment Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratios in Multiple Myeloma Patients Treated with Thalidomide-based Regimen

Overview

Journal Ann Hematol

Specialty Hematology

Date 2020 May 28

PMID 32458064

Citations 10

Authors

Aneta Szudy-Szczyrek

Radoslaw Mlak

Michal Mielnik

Michal Szczyrek

Aleksandra Nowaczynska

Iwona Homa-Mlak

Szymon Zmorzynski

Kinga Kusmierczuk

Jacek Sompor

Agata Filip

Teresa Malecka-Massalska

Marek Hus

Affiliations

Soon will be listed here.

Abstract

Neutrophils to lymphocytes ratio (NLR) and platelets to lymphocytes ratio (PLR) are considered as laboratory markers of inflammation. They can be potentially useful in predicting the course of multiple neoplasms including selected hematological cancers. The aim of the study was to assess the value of NLR and PLR in predicting the effects of therapy and prognosis in multiple myeloma patients treated with thalidomide-based regimen. The study group consisted of 100 patients treated with the first line CTD (cyclophosphamide, thalidomide, and dexamethasone) chemotherapy. The NLR and PLR were calculated before treatment. High NLR was observed in patients with higher stage of the disease, with poor performance status, hypercalcemia, and high CRP. High PLR was associated with low BMI and high CRP. In patients with high NLR, significantly shorter PFS was observed (17 vs. 26 months, p = 0.0405). In addition, high values of NLR and PLR were associated with significantly shorter OS (38 vs. 79 months, p = 0.0010; 40 vs. 78 months, p = 0.0058). Summarizing, NLR and PLR have a significant independent prognostic value for multiple myeloma patients. Furthermore, the NLR can be a predictive marker for the outcome of thalidomide-based chemotherapy.

Citing Articles

A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients.

Wang M, Yue X, Ding Y, Cai Z, Xiao H, Huang H J Inflamm Res. 2025; 18:2077-2090.

PMID: 39959644 PMC: 11829637. DOI: 10.2147/JIR.S495284.

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen.

Zhang Q, Wang Y, Shi W, Chen Y, He Z, Yu L Sci Rep. 2025; 15(1):1819.

PMID: 39805912 PMC: 11731002. DOI: 10.1038/s41598-024-84343-x.

How Immunonutritional Markers Are Associated with Age, Sex, Body Mass Index and the Most Common Chronic Diseases in the Hospitalized Geriatric Population-A Cross Sectional Study.

Stephenson S, Kravchenko G, Korycka-Bloch R, Kostka T, Soltysik B Nutrients. 2024; 16(15).

PMID: 39125344 PMC: 11314227. DOI: 10.3390/nu16152464.

An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.

de Jong M, Fokkema C, Papazian N, Czeti A, Appelman M, Vermeulen M Nat Immunol. 2024; 25(5):820-833.

PMID: 38600356 DOI: 10.1038/s41590-024-01808-x.

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma.

Wang Y, Man Q, Li C Pak J Med Sci. 2023; 39(5):1243-1248.

PMID: 37680825 PMC: 10480731. DOI: 10.12669/pjms.39.5.6815.

References

Shi L, Qin X, Wang H, Xia Y, Li Y, Chen X . Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2016; 8(12):18792-18801. PMC: 5386647. DOI: 10.18632/oncotarget.13320. View

Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S . Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002; 9(3):287-91. DOI: 10.1007/BF02573067. View

Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J . Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 2014; 9(6):e101119. PMC: 4072728. DOI: 10.1371/journal.pone.0101119. View

Shalapour S, Karin M . Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015; 125(9):3347-55. PMC: 4588298. DOI: 10.1172/JCI80007. View

Mu S, Ai L, Fan F, Sun C, Hu Y . Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis. Onco Targets Ther. 2018; 11:499-507. PMC: 5788996. DOI: 10.2147/OTT.S153146. View

Zeng Q, Liu Z, Li Q, Liu T . Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: A meta-analysis. Medicine (Baltimore). 2018; 97(41):e12678. PMC: 6203562. DOI: 10.1097/MD.0000000000012678. View

Solmaz S, Uzun O, Acar C, Sevindik O, Piskin O, Ozsan H . Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?. J Lab Physicians. 2018; 10(4):363-369. PMC: 6210833. DOI: 10.4103/JLP.JLP_36_18. View

Kelkitli E, Atay H, Cilingir F, Guler N, Terzi Y, Ozatli D . Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio. Ann Hematol. 2013; 93(5):841-6. DOI: 10.1007/s00277-013-1978-8. View

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

10.

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

11.

Kishi Y, Kopetz S, Chun Y, Palavecino M, Abdalla E, Vauthey J . Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009; 16(3):614-22. DOI: 10.1245/s10434-008-0267-6. View

12.

Podar K, Chauhan D, Anderson K . Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2008; 23(1):10-24. PMC: 3418600. DOI: 10.1038/leu.2008.259. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Reagan M, Ghobrial I . Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2011; 18(2):342-9. PMC: 3261316. DOI: 10.1158/1078-0432.CCR-11-2212. View

15.

Onec B, Okutan H, Albayrak M, Can E, Aslan V, Koluman B . The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experience. J Clin Lab Anal. 2016; 31(2). PMC: 6817132. DOI: 10.1002/jcla.22032. View

16.

Templeton A, Ace O, McNamara M, Al-Mubarak M, Vera-Badillo F, Hermanns T . Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014; 23(7):1204-12. DOI: 10.1158/1055-9965.EPI-14-0146. View

17.

Wang D, DuBois R . Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015; 36(10):1085-93. PMC: 5006153. DOI: 10.1093/carcin/bgv123. View

18.

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

19.

Cannon N, Meyer J, Iyengar P, Ahn C, Westover K, Choy H . Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol. 2014; 10(2):280-5. DOI: 10.1097/JTO.0000000000000399. View

20.

Shau H, Kim A . Suppression of lymphokine-activated killer induction by neutrophils. J Immunol. 1988; 141(12):4395-402. View